If you need to contact our communication department, please do it by contacting:

  • Miguel Martínez-Cava
  • Olaya Fernández Díez
  • Pharma Mar Communication Dept.
  • Phone: +34 91 846 6000

Press releases

No posts found.

Sylentis – Treatment commences for first patients in Phase I/II clinical trial with SYL040012

SYL040012 is a new compound developed in Sylentis’s R&D programme in ophthalmological disorders such as ocular hypertension and glaucoma. SYL040012 is a form of RNA interference (RNAi). It reduces intraocular pressure by inhibiting the expression of ß-adrenergic receptors. Madrid, 22 November 2010: Sylentis, a biopharmaceutical subsidiary of Grupo Zeltia (MC: ZEL)

Sylentis receives authorisation to commence Phase IIb clinical trial with bamosiran (SYL040012) for treating ocular hypertension associated with glaucoma

The main endpoint of the trial is to establish the most effective dose of bamosiran for reducing intraocular pressure after 28 days’ treatment.  The Phase IIb trial with bamosiran will be conducted at 21 centres in Spain, Germany, Estonia and the United States, enrolling 180 patients. Madrid, 17 July 2014: Grupo

Sylentis announces new data on the treatment of allergic conjunctivitis

The results of SYL116011 have demonstrated that this treatment reduces the symptoms related to the allergy in 50% to 80%. The ARVO meeting has considered the poster presentation to be of scientific interest, contributing therefore to its release. Around 30% of the worldwide population show allergic symptoms and between 40-80%

FDA authorizes Sylentis (PharmaMar Group) to initiate Phase III trial with tivanisiran for the treatment of dry eye disease

This Phase III study, called SYL1001_V, will involve more than 30 hospitals in the United States. It will evaluate the efficacy and safety of tivanisiran ophthalmic solution on the signs and symptoms of patients with dry eye disease associated with Sjögren’s Syndrome. The study has been approved by the FDA